Trial Profile
An Open-label, Multicenter, Expanded Access Program for Asfotase Alfa (human recombinant tissue-nonspecific alkaline phosphatase fusion protein) Treatment for Patients with Infantile- or Juvenile-onset Hypophosphatasia (HPP)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Nov 2023
Price :
$35
*
At a glance
- Drugs Asfotase alfa (Primary)
- Indications Hypophosphatasia
- Focus Adverse reactions; Expanded access
- Sponsors Alexion AstraZeneca Rare Disease
- 28 Oct 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 16 Jul 2015 New trial record